emtricitabine + tenofovir disoproxil phosphate · Medicine question

Which HIV-1 mutation is a reason to avoid emtricitabine/tenofovir disoproxil in patients previously treated with antiretrovirals?

Name: Which HIV-1 mutation is a reason to avoid emtricitabine/tenofovir disoproxil in patients previously treated with antiretrovirals?
Published: 2026-11-08T01:48:32.035Z

iatroX medicinesPublished 8 November 2026

The answer

Answer

Emtricitabine/tenofovir disoproxil should be avoided in patients previously treated with antiretrovirals whose HIV-1 harbours the K65R mutation.

Sources for this answer

Emtricitabine/Tenofovir disoproxil Lupin 200 mg/245 mg Film-coated TabletsLupin Healthcare (UK) Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 6Document updated 5 February 2025

Sources checked 8 November 2026

loading page…

Answer

Sources for this answer

Answer

Sources for this answer

More questions about emtricitabine + tenofovir disoproxil phosphate